Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech firm focused on stem cell therapies for rare pediatric and aging-related diseases, disclosed its full-year 2025 financial results and key business developments. The company highlighted progress in its lead program for hypoplastic left heart syndrome (HLHS) while securing new funding.
Financial Highlights
Revenues for 2025 totaled $1.2 million, down 50% from $2.4 million in 2024. Clinical trial revenue contributed $1.0 million, supplemented by $0.2 million from contract manufacturing. Gross profit fell to $0.8 million from $1.9 million the prior year.
Operating expenses rose, with research and development at $12.0 million (up 48%) and general and administrative costs at $12.0 million (up 17%). This led to an operating loss of $23.3 million and a net loss of $22.7 million, compared to $16.0 million in 2024.
Cash and equivalents stood at $4.7 million as of December 31, 2025. Recent financing bolsters the runway: Longeveron closed an initial $15 million tranche of a private placement worth up to $30 million, led by Coastlands Capital and Janus Henderson Investors, with additional funds tied to HLHS trial milestones.
Pipeline and Clinical Progress
Longeveron advances laromestrocel (Lomecel-B), an allogeneic bone marrow-derived stem cell therapy with regenerative and anti-inflammatory properties.
Hypoplastic Left Heart Syndrome (HLHS)
The pivotal Phase 2b ELPIS II trial remains on schedule for top-line results in Q3 2026. Positive outcomes could support a Biologics License Application (BLA) submission in 2027. The program holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations, potentially qualifying for a Priority Review Voucher (PRV). Longeveron plans a Type C FDA meeting by late March 2026 to align on endpoints.
Alzheimer’s Disease (AD)
Phase 2a CLEAR MIND data, published in Nature Medicine, demonstrated benefits linked to reduced neuroinflammation. A positive FDA Type B meeting outlined a path to BLA via a single pivotal Phase 2/3 trial. RMAT and Fast Track designations apply.
Pediatric Dilated Cardiomyopathy (PDCM)
IND clearance enables a pivotal Phase 2 trial start in 2027. The therapy targets a condition with high mortality in children.
Strategic Updates
Longeveron pursues partnerships to accelerate development across its pipeline, targeting markets exceeding $7 billion combined. Recent patents cover uses in frailty, cardiomyopathy, and more. Stephen H. Willard assumed CEO role in February 2026, bringing extensive biotech experience.
“With a strong foundation in stem cell science and multiple positive clinical trials… Longeveron is well positioned to be a leader in advancing stem cell treatments,” stated Stephen Willard, Chief Executive Officer. “We continue to focus on delivering top-line trial results in the third quarter of 2026 for our anticipated pivotal Phase 2b clinical trial evaluating laromestrocel as a potential treatment for HLHS.”
The company hosted a conference call on March 17, 2026, with a replay available on its investor website.
